Both mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) are authorized and recommended in the United States for protection against hospital-related COVID-19 among adults 65 years and older, according to a recent CDC assessment that finds fully vaccinated adults 65 years and older are about 94% less likely to be hospitalized with COVID-19 than people of the same age who have not been vaccinated. People 65 and older who were partially vaccinated were 64% less likely to be hospitalized with COVID-19 than people who were not vaccinated. People were considered “partially vaccinated” two weeks after their first dose of mRNA vaccine and “fully vaccinated” two weeks after their second dose.
These are the first real-world findings in the United States confirming clinical trial data showing the mRNA vaccine to prevent severe COVID-19 disease. The findings provide additional support for the CDC’s recommendation for COVID-19 vaccination in people 65 and older in the U.S. population under Emergency Use Authorization (EUA) for the use of the COVID-19 vaccine as the risk for severe disease with COVID-19 increases with age, with older adults at highest risk.
“These findings inspire good news for two-thirds of people age 65 and older who are already fully vaccinated,” said CDC Director Rochelle P. Walensky, MD, MPH. “COVID-19 vaccine is very effective and these real-world findings confirm the benefits seen in clinical trials, preventing hospitalization among the most vulnerable. The results are promising for our communities and hospitals. While the our vaccination efforts continue to expand., COVID-19 patients do not overlap with the health care system-leaving hospital staff, beds, and services available for people who need them for others. medical conditions of “
the assessment looked at hospitalization in two U.S. hospital networks comprising 24 hospitals out of 14 states. The effectiveness of the vaccine was evaluated by comparing the possibilities of COVID-19 vaccination among hospitalized patients who tested positive for COVID-19 virus (these are case-patients) versus those who tested negative (these are controls). Among the 417 study participants, there were 187 case-patients and 230 controls. Nearly half of the patients were over 75 years of age.
Also noteworthy, while early reports from Israel also documented the true effectiveness of COVID-19 vaccination, including among the elderly, the reports only looked at the Pfizer-BioNTech vaccine. . In this CDC review, both Pfizer-BioNTech and Moderna vaccine products were equally represented.
As expected, the assessment confirmed vaccination was given without protection to people who had received their first dose less than two weeks earlier. It takes two weeks for the body to form a resistance response after vaccination.
Two networks previously established on behavioral surveillance for serious influenza disease provide data for its assessment: Hospital Adult Influenza Vaccine Effective Network (HAIVEN) and Effective Influenza Vaccine in Influenza (IVY).
assessment This is one of several COVID-19 vaccine effective assessments to evaluate the real-world benefits of the COVID-19 vaccine. Results from these reviews will help inform vaccine policy decisions aimed at saving lives and reducing severe COVID-19 disease as much as possible.
The CDC recommends all 16 years of age and older in the U.S. population under the EUA get the hit COVID-19 vaccine as soon as possible.